Drug Type Contrast agent, Small molecule drug |
Synonyms Gadodiamide (USP/INN), Gadodiamide anhydrous, Gadodiamide Hydrate + [8] |
Target- |
Mechanism Magnetic resonance imaging enhancers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (08 Jan 1993), |
Regulation- |
Molecular FormulaC16H26GdN5O8 |
InChIKeyHZHFFEYYPYZMNU-UHFFFAOYSA-K |
CAS Registry131410-48-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04284 | Gadodiamide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Contrast agents | US | 08 Jan 1993 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Renal Artery Obstruction | Phase 3 | DE | 01 Sep 2003 | |
Nephrogenic Fibrosing Dermopathy | Preclinical | US | 23 Oct 2018 |
Phase 4 | 213 | tndvtzbebv(cqgekdsynw) = xyvtrnjlyz cvxfnuqwks (oszgkttpfw, illqahmiuh - nygudetogf) View more | - | 17 Jul 2014 |